GLP-1 drugs and eating disorders: what TikTok gets wrong
Quick answer
The transcript references perceived weight gain without specifying a medication, dose, or diagnosis, making direct clinical evaluation impossible. However, the GLP-1 category tag places this in a space where semaglutide and tirzepatide are the primary pharmacological context, both of which have robust clinical trial data showing substantial weight reduction, not gain, during active treatment. The eating disorder-coded hashtags raise a separate and serious clinical concern about audience vulnerability and the appropriateness of weight-focused humor in that community.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @imaginary.magdeline actually say?
The claim here is thin, literally. The creator says they believe they are "getting kinda chubby" and frames this as something a mother figure would want people to understand, offering it as a form of help. That is essentially the full substance of the health-relevant content. This video is tagged under GLP-1 content, which means the implication, whether intended or not, is that GLP-1 medication use is connected to the weight observation.
The hashtags tell a more complicated story. Tags like #ana and #bed alongside #copingwithhumor suggest this video may be embedded in eating disorder community spaces, where weight gain commentary carries very different weight, no pun intended. The "ED Sheeran" hashtag appears to be a common workaround to avoid content moderation on eating disorder topics. That context matters enormously when evaluating what this video is actually communicating and to whom.
Does the science back this up?
There is no coherent scientific claim to evaluate here, because the transcript does not make one. What we can do is address the implied territory: GLP-1 receptor agonists and weight change. On that front, the science is actually pretty clear, and it goes in the opposite direction of "getting chubby."
Semaglutide, the active ingredient in Ozempic and Wegovy, produced an average body weight reduction of 14.9% over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide, studied in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), showed reductions up to 22.5% in the highest dose group. These are not subtle effects. GLP-1 medications are among the most effective pharmacological tools for weight reduction ever studied in large randomized controlled trials.
Weight gain on GLP-1 medications does happen, but almost exclusively after stopping them. Davies et al. (2023, Diabetes, Obesity and Metabolism) found significant weight regain within one year of discontinuation. So if someone is "getting kinda chubby" while on a GLP-1, that warrants a clinical conversation, not a TikTok caption.
What did they get wrong (or right)?
Wrong: If the implication is that GLP-1 use causes weight gain during active treatment, that is not supported by the evidence. The major clinical trials show consistent, significant weight loss as the primary outcome. Framing GLP-1 use and weight gain as connected, even obliquely, spreads confusion in a space that is already crowded with misinformation.
Right: The creator does not make any specific dosing claims, does not name a medication, and does not tell anyone what to take. That keeps the video from crossing into the more dangerous territory of unqualified medical advice. Credit where it is due.
The bigger concern is contextual. Posting weight-related content with eating disorder-coded hashtags, even under the banner of humor, can reinforce harmful body image narratives for a vulnerable audience. A 62,800-view video is not a private conversation. The #copingwithhumor framing does not neutralize the potential impact on someone already struggling with disordered eating.
What should you actually know?
If you are on a GLP-1 medication and experiencing unexpected weight gain, there are legitimate clinical explanations worth discussing with your prescriber. These include inadequate dosing for your individual metabolism, medication non-adherence, hormonal factors, or changes in appetite signaling that vary person to person. It does not mean the drug is not working for everyone, and it does not mean you should self-adjust your dose.
If you are in an eating disorder recovery space and encountering GLP-1 content, that intersection is genuinely complicated. Research is actively examining whether GLP-1 agonists are appropriate for people with restrictive eating disorder histories. Giel et al. (2023, European Eating Disorders Review) raised caution about using appetite-suppressing medications in populations where reduced appetite is already a pathological feature. This is not settled science, and your care team needs to be part of that conversation.
FormBlends is a regulated telehealth platform. We do not recommend specific doses, and we do not claim compounded GLP-1 products are equivalent to FDA-approved brand-name drugs. If you have questions about GLP-1 therapy, that conversation belongs with a licensed clinician who knows your full medical history.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and eating disorders: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and eating disorders: what TikTok gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The transcript references perceived weight gain without specifying a medication, dose, or diagnosis, making direct clinical evaluation impossible.
FormBlends verdict
The transcript references perceived weight gain without specifying a medication, dose, or diagnosis, making direct clinical evaluation impossible. However, the GLP-1 category tag places this in a space where semaglutide and tirzepatide are the primary pharmacological context, both of which have robust clinical trial data showing substantial weight reduction, not gain, during active treatment. The eating disorder-coded hashtags raise a separate and serious clinical concern about audience vulnerability and the appropriateness of weight-focused humor in that community.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The transcript references perceived weight gain without specifying a medication, dose, or diagnosis, making direct clinical evaluation impossible. However, the GLP-1 category tag places this in a space where semaglutide and tirzepatide are the primary pharmacological context, both of which have robust clinical trial data showing substantial weight reduction, not gain, during active treatment. The eating disorder-coded hashtags raise a separate and serious clinical concern about audience vulnerability and the appropriateness of weight-focused humor in that community.
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide produced average 14.9% body weight reduction over 68 weeks, not weight gain.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at the highest dose produced up to 22.5% weight reduction, among the largest pharmacological effects ever recorded.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- STEP 1 trial (Wilding et al., 2021, NEJM): semaglutide produced average 14.9% body weight reduction over 68 weeks, not weight gain.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide at the highest dose produced up to 22.5% weight reduction, among the largest pharmacological effects ever recorded.
- Weight gain after GLP-1 use is real but occurs primarily post-discontinuation: Davies et al. (2023, Diabetes, Obesity and Metabolism) documented significant regain within one year of stopping.
- The hashtag #ana is a known eating disorder community signal, and weight-gain content in that context carries documented risk for reinforcing harmful behaviors regardless of humorous intent.
- Giel et al. (2023, European Eating Disorders Review) flagged concerns about using appetite-suppressing GLP-1 medications in patients with restrictive eating disorder histories, a population that may overlap significantly with this video's audience.
- Unexpected weight gain during active GLP-1 treatment warrants clinical evaluation, not social media content, as individual metabolic responses vary and dose adequacy should be assessed by a licensed prescriber.
- Compounded GLP-1 products are not equivalent to FDA-approved brand-name semaglutide or tirzepatide formulations. If you have questions about your specific medication, consult your care team.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
𝘮𝘢𝘨𝘨𝘪𝘦 · TikTok creator
62.8K views on this video
#copingwithhumor #EDsheeran #playED #ana #bed
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by 𝘮𝘢𝘨𝘨𝘪𝘦, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.